Patents Examined by Nianxiang Zou
  • Patent number: 10654914
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: May 19, 2020
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • Patent number: 10655109
    Abstract: Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: May 19, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Ursula J. Buchholz, Cindy Luongo
  • Patent number: 10639363
    Abstract: A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 5, 2020
    Assignee: CASE WESTERN REVERSE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Amy M. Wen, Steven Fiering, Patrick H. Lizotte
  • Patent number: 10626150
    Abstract: The invention provides a Gene sequence which can encode and express adenovirus hexon protein in vitro, and is represented as SEQ ID NO: 3. Also invented a protein which was translated and expressed by the gene sequence according to the invention, and the invention also relates to the use of the protein as an antigen to immunize rabbits to obtain a polyclonal antibody. The antibody mentioned above can detect adenovirus with high sensitivity and specificity.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: April 21, 2020
    Assignee: JIAXING ANYU BIOTECHNOLOGY CO., LTD.
    Inventors: Ping Chen, Na Li, Xintao Zhong, Tingting Zhang, Nan Li
  • Patent number: 10611803
    Abstract: The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: April 7, 2020
    Assignee: University of Washington Through Its Center For Commercialization
    Inventors: Andre Lieber, Hongjie Wang
  • Patent number: 10610587
    Abstract: This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 7, 2020
    Assignee: CELLTRION INC.
    Inventors: Shin Jae Chang, Soo Young Lee, Byung Pil Lim, Pan Kyeom Kim, Sang Tae Park, Jung Sun Ahn, Eun Bee Park, Sun Ju Keum, Man Ki Song, Jung Ah Choi
  • Patent number: 10605809
    Abstract: A rapid test for a qualitative and/or quantitative assay of antibodies present in body fluid against human papilloma viruses (HPV) includes mixing a specimen of body fluid with a reagent which essentially comprises a predetermined quantity of physiologically acting liquid and a predetermined quantity of at least one HPV-specific antigen. The mixture is fed to an analysis which utilizes a change that is at least one of measurable or perceivable by a user.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: March 31, 2020
    Assignee: ABVIRIS DEUTSCHLAND GMBH
    Inventor: Ralf Hilfrich
  • Patent number: 10596248
    Abstract: Disclosed are therapeutic compositions and methods for inducing an immune response to human papillomavirus (HPV). More particularly, disclosed is a method for inducing an immune response in a subject by introducing and expressing a nucleic acid molecule encoding an immunogenic HPV antigen.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 24, 2020
    Assignee: Jingang Medicine (Australia) Pty Ltd
    Inventors: Julie Dutton, Ian Frazer
  • Patent number: 10596253
    Abstract: The present invention provides vaccines for treating or preventing a herpes simplex virus infection and methods of using and making the vaccine. Further provided are recombinant herpes simplex virus genomes, recombinant viruses, and immunogenic compositions.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: March 24, 2020
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Konstantin G. Kousoulas
  • Patent number: 10588958
    Abstract: The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 17, 2020
    Assignee: University of Georgia Research Foundations, Inc.
    Inventor: Holly S. Sellers
  • Patent number: 10590204
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 17, 2020
    Assignee: KATINGER GMBH
    Inventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
  • Patent number: 10584329
    Abstract: The invention generally relates to methods for universal target capture.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: March 10, 2020
    Assignee: DNAE Group Holdings Limited
    Inventor: Colin Dykes
  • Patent number: 10570416
    Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: February 25, 2020
    Assignee: ALPHAVAX, INC.
    Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
  • Patent number: 10561723
    Abstract: The invention relates to methods, compositions, and kits for treating a condition with an immune response modifier and a human papillomavirus (HPV) vaccine. Conditions treatable with the methods, kits and compositions include but are not limited to neoplasia, anal intraepithelial neoplasia, high-grade squamous intraepithelial neoplasia, dysplasia, anal dysplasia, dysplastic lesion, high-grade dysplastic lesion, condyloma, anal cancer, anal tumor, HPV infection, and any HPV-induced condition.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 18, 2020
    Inventor: Steven Frederick Scheibel
  • Patent number: 10561730
    Abstract: Photodynamic virus particles including a plant virus particle associated with a photosensitizing agent are described. Methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the photodynamic virus particles and illuminating a cancer-bearing region of the subject to activate the photodynamic virus particles are also described.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: February 18, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Nicole F. Steinmetz
  • Patent number: 10555996
    Abstract: Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 11, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Evelien Margaretha Bunnik, Jerôme Hubertina Henricus Victor Custers, Gerrit Christiaan Scheper, Koen Oosterhuis, Taco Gilles Uil, Selina Khan
  • Patent number: 10548971
    Abstract: Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 4, 2020
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David Weiner, Karuppiah Muthumani, Niranjan Y. Sardesai
  • Patent number: 10544430
    Abstract: The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: January 28, 2020
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Maoli Yuan, Kevin Wright, Christy Jurgens
  • Patent number: 10537629
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: January 21, 2020
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
  • Patent number: 10519219
    Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: December 31, 2019
    Assignees: The Secretary of State for Health, MicroPharm Limited, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Miles Carroll, Stuart Dowall, Roger Hewson, Ian Cameron, John Landon, Antra Zeltina, David Stuart, Thomas Bowden